ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 8, 2021

8:30AM-10:30AM: Abstract Number: 1285

Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1004

Manipulation of B7 Family Member Expression Demonstrates Synovial Macrophage Plasticity and Possible Future Targets for Treatment of Rheumatoid Arthritis

Innate Immunity Poster (0992–1006)

8:30AM-10:30AM: Abstract Number: 1166

Marijuana Use Amongst Rheumatology Patients: It’s More Common Than Rheumatologists Believe

Patient Outcomes, Preferences, & Attitudes Poster III: Patient Preferences (1153–1169)

8:30AM-10:30AM: Abstract Number: 1258

Measurement of Specific Organ Domains in Lupus Randomised Controlled Trials

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1386

Measurement of TIMP-1 in Pulmonary Vessels May Be a Novel Marker of Reflecting mPAP in CTD-PH

Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

8:30AM-10:30AM: Abstract Number: 1024

Medical Care Seeking Is Frequent and Associated with Overuse of Low-Value Care for Low Back Pain in Portugal: Results from a Nationwide Population-Based Study

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1054

Metabolomics as an Innovative Tool for Cardiac Risk Stratification in Patients with Rheumatic Diseases: Results from a Pilot Study

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1244

Mindfulness-Based Stress Reduction (MBSR) to Improve Patient-Related Outcomes (PROs) in Patients with Rheumatoid Arthritis in Clinical Remission but Elevated Negative PROs: A Pragmatic Pilot Study

RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)

8:30AM-10:30AM: Abstract Number: 1000

Molecular Mechanism of Inhibition of CD38 in Attenuation of Monosodium Urate Crystal-induced Inflammatory Responses in Macrophages

Innate Immunity Poster (0992–1006)

8:30AM-10:30AM: Abstract Number: 1040

Monoclonal Gammopathy in Autoimmune Diseases: Analysis and Follow-up of 160 Cases in a Tertiary Center in China

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1108

More Frequent, Earlier Hip Involvement and Poor Outcome in Spondyloarthritis Associated with Familial Mediterranean Fever

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

8:30AM-10:30AM: Abstract Number: 1196

Morning Stiffness Already Associates with Systemic Inflammation and Subclinical Joint Inflammation in the Pre-RA Phase of Arthralgia

RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)

8:30AM-10:30AM: Abstract Number: 1296

Mortality and Survival in Argentinian Lupus Patients: A Multicenter Study

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1049

Multimorbidity Differences Between Systemic Lupus Erythematosus Patients and Comparators in Different Age Groups: A Large Nationwide US Study

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1042

Multimorbidity Prevalence in Systemic Lupus Erythematosus: A Population-Based Study

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].